By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biodesix said on Tuesday that it has received certification from the New York State Department of Health to offer its VeriStrat serum proteomic test.

As a result, the test, which is to help guide doctors in the treatment of patients with non-small cell lung cancer, is available in all 50 states. The test is performed in Biodesix's CLIA laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.